6 completed. 6 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 6 | Completed 6 |
Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit - Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 4 | Completed | Vanderbilt-Ingram Cancer Center | 25 | 2021-12-02 | 2025-03-27 |
| Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma Apatinib - Relapsed and Refractory, Diffuse Large B Cell Lymphoma | Phase 4 | Completed | Zhengzhou University | 32 | 2017-01-01 | 2019-07-25 |
| A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma Brentuximab Vedotin - Hodgkin Lymphoma | Phase 4 | Completed | Millennium Pharmaceuticals, Inc. | 60 | 2014-03-14 | 2021-04-09 |
| LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV) R-CHOP, Highly active antiretroviral therapy, Central nervous system (CNS) prophylaxis - HIV Infections, Diffuse Large B Cell Lymphoma | Phase 4 | Completed | PETHEMA Foundation | 50 | 2006-10-01 | 2009-11-25 |
| Newly Diagnosed Mature B-ALL, Burkitt's Lymphoma and Other High-grade Lymphoma in Adults Adriamycin, Cyclophosphamide, Cytarabine - Burkitt's Lymphoma, Burkitt's Leukemia | Phase 4 | Completed | Nicola Goekbuget | 650 | 2002-07-01 | 2022-08-19 |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cyclophosphamide - Anemia, Graft Versus Host Disease | Phase 4 | Completed | University of Maryland, Baltimore | 45 | 1998-09-01 | 2019-10-17 |
Lymphoma, Large B-Cell, Diffuse (5) · Recurrence (3) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Anemia (1) · Blast Crisis (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1) · HIV Infections (1) · Hematologic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1)
Hemic and Lymphatic Diseases (6) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphoma (4) · Disease Attributes (3) · Infections (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Virus Diseases (3)
Cyclophosphamide (3) · Antilymphocyte Serum (1) · Antiretroviral Therapy, Highly Active (1) · Blood Pressure (1) · Brentuximab Vedotin (1) · Cytarabine (1) · Dexamethasone (1) · Doxorubicin (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Ifosfamide (1) · Methotrexate (1) · Nurse Clinicians (1) · Prednisolone (1)
Millennium Pharmaceuticals, Inc. (1) · Nicola Goekbuget (1) · PETHEMA Foundation (1) · University of Maryland, Baltimore (1) · Vanderbilt-Ingram Cancer Center (1) · Zhengzhou University (1)
Germany (2) · Spain (2) · United States (2) · China (1) · Czechia (1) · Malaysia (1) · Poland (1) · Thailand (1) · Turkey (Türkiye) (1)
Barry R. Meisenberg, MD (1) · Nicola Goekbuget, Dr. med. (1) · Olalekan Oluwole, MD (1) · Oriol Albert, Dr (1) · Ribera Josep M, Dr (1)